^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
PRGN-3007
i
Other names: PRGN-3007, PRGN 3007
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Precigen
Drug class:
PD1 inhibitor, ROR1-targeted CAR-T immunotherapy
Related drugs:
10d
MCC-21622: Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies (clinicaltrials.gov)
P1, N=3, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Jan 2026 --> Mar 2025
Trial primary completion date • CAR T-Cell Therapy • Metastases
|
cyclophosphamide • fludarabine IV • PRGN-3007
13d
MCC-21622: Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies (clinicaltrials.gov)
P1, N=3, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | N=88 --> 3
Enrollment closed • Enrollment change • CAR T-Cell Therapy • Metastases
|
cyclophosphamide • fludarabine IV • PRGN-3007
2years
A Phase1/1b Dose Escalation/Dose Expansion Study of Prgn-3007 Ultracar-T Cells in Patients with Advanced Hematologic and Solid Tumor Malignancies (ASH 2022)
Study subjects undergo leukapheresis followed by lymphodepletion with either fludarabine 30mg/m2 and cyclophosphamide 500mg/m2 for 3 days (Arm 1) or 60 mg/kg cyclophosphamide for 2 days (Arm 2). All subjects will be followed for adverse events, CAR-T-related toxicities, disease response and PRGN-3007 cell expansion and persistence. In addition, the mechanisms of safety and effectiveness of PRGN-3007 cells will be evaluated with correlative assays of specific immune response pathways.
Clinical • P1 data • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CCND1 (Cyclin D1) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • IL15 (Interleukin 15)
|
PD-1 expression • ROR1 expression • CCND1 overexpression
|
cyclophosphamide • fludarabine IV • Ovarian cancer CAR-T therapy • PRGN-3005 • PRGN-3007
3years
Preclinical Evaluation of Prgn-3007, a Non-Viral, Multigenic, Autologous ROR1 Ultracar-T® Therapy with Novel Mechanism of Intrinsic PD-1 Blockade for Treatment of Hematological and Solid Cancers (ASH 2021)
Data shown is from 8 mice/group at the start of the study. * p<0.05, ***p<0.001; log rank test.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
|
PD-1 expression • ROR1 expression
|
PRGN-3005 • PRGN-3007
Share via
